Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday

Annexon (NASDAQ:ANNX) is expected to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Annexon Trading Up 4.1%

Shares of NASDAQ:ANNX opened at $5.60 on Friday. The firm has a 50 day moving average of $5.61 and a 200-day moving average of $4.04. The stock has a market capitalization of $669.93 million, a PE ratio of -3.97 and a beta of 1.17. Annexon has a 12 month low of $1.28 and a 12 month high of $7.18.

Analyst Ratings Changes

ANNX has been the topic of a number of recent analyst reports. Chardan Capital began coverage on shares of Annexon in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Wells Fargo & Company boosted their price target on Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Insider Buying and Selling

In other news, Director Jung Choi acquired 33,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were bought at an average price of $4.19 per share, with a total value of $138,270.00. Following the acquisition, the director directly owned 33,000 shares in the company, valued at $138,270. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Ted Yednock sold 7,857 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total value of $40,149.27. Following the completion of the transaction, the executive vice president directly owned 97,227 shares of the company’s stock, valued at approximately $496,829.97. The trade was a 7.48% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders purchased 41,230 shares of company stock worth $177,321 and sold 32,513 shares worth $165,973. 11.87% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new stake in Annexon during the 3rd quarter worth approximately $31,000. Engineers Gate Manager LP acquired a new position in shares of Annexon during the second quarter worth $32,000. Landscape Capital Management L.L.C. bought a new stake in shares of Annexon in the fourth quarter worth $50,000. Mercer Global Advisors Inc. ADV acquired a new stake in Annexon in the fourth quarter valued at $52,000. Finally, Russell Investments Group Ltd. bought a new position in Annexon during the 3rd quarter worth $56,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.